🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Orchid Pharma Limited ORCHPHARMA NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.orchidpharma.com
Company Profile ↓
₹1,073.70
+48.52% 1Y
Mkt Cap₹5,445.71 Cr
P/E54.64
P/B3.97
52W High₹1,073.70
52W Low₹482.45
Book Value₹253.91
EPS (TTM)₹19.65

Company Overview

Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited.

Why Investors Should Care

Healthy Margins

Operating margin of 19.5% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.28.

Recent Developments

  • Mar 2026 Revenue of ₹811.33 Cr (-12.0% YoY); net profit ₹20.55 Cr.
  • Trailing 12 Months Year-on-year growth — revenue -12.0%, earnings -79.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 6.8%, profit CAGR -23.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:6.81%
1 Year:-12.00%

Compounded Profit Growth

5 Years:-23.73%
1 Year:-79.38%

Stock Price Performance

1 Year:+48.52%
6 Months:+47.39%
3 Months:+89.80%
1 Month:+11.74%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
₹482.45 ₹1,073.70
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)67.62 · Neutral
Price Performance
1M+11.74%
3M+89.80%
6M+47.39%
1Y+48.52%
Valuation vs Sector

P/E of 54.64 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 54.6.
  • Earnings shrank at -23.7% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
54.64
Industry PE
39.97
Forward P/E
33.45
PEG Ratio
-
Book Value
₹253.91
Price to Book
3.97
P/S
8.44
EV/EBITDA
78.38
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
6.81%
Profit 5Y
-23.73%
Revenue (YoY)
-12.00%
Earnings (YoY)
-79.38%

Profitability & Returns

ROCE
2.10%
ROE
1.60%
ROA
1.08%
Profit Margin
2.53%
Op Margin
19.54%
Gross Margin
35.18%
EPS (Latest Qtr)
₹4.69
EPS (TTM)
₹19.65

Balance Sheet & Liquidity

Debt/Equity
0.28
Quick Ratio
1.53
Current Ratio
2.45
Debt
₹362.59 Cr
Total Assets
₹1,910.91 Cr
Current Assets
₹683.90 Cr
Working Capital
₹404.93 Cr

Ownership

Promoter Holding
69.84%
Chg in Prom Hold
-0.00%
FII / Inst Holding
18.05%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
₹5,445.71 Cr
Total Revenue (TTM)
₹811.33 Cr
EBITDA
₹69.73 Cr
Free Cash Flow
₹-282.39 Cr
Operating Cash Flow
₹101.20 Cr
Shares Outstanding
₹5.07 Cr
Gross Margin
35.18%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ORCHPHARMA Orchid Pharma Limited NSEPHARMA 1,073.70 54.64 ₹5,445.71 Cr 0.00% 2.10% 1.60% 6.81% -23.73%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 210.00 Cr183.00 Cr199.00 Cr221.00 Cr217.00 Cr244.00 Cr-217.00 Cr237.48 Cr172.93 Cr193.52 Cr207.27 Cr237.61 Cr
Cost of Revenue --------138.02 Cr98.87 Cr132.51 Cr143.15 Cr151.36 Cr
Gross Profit --------99.46 Cr74.06 Cr61.02 Cr64.12 Cr86.25 Cr
Operating Expenses 170.00 Cr161.00 Cr175.00 Cr185.00 Cr188.00 Cr212.00 Cr-191.00 Cr31.11 Cr68.54 Cr71.39 Cr33.16 Cr29.75 Cr
Operating Income 33.00 Cr14.00 Cr15.00 Cr26.00 Cr21.00 Cr24.00 Cr-17.00 Cr68.35 Cr5.52 Cr-10.38 Cr30.96 Cr56.50 Cr
EBITDA 40.00 Cr22.00 Cr23.00 Cr35.00 Cr29.00 Cr32.00 Cr-26.00 Cr31.88 Cr25.62 Cr9.30 Cr6.07 L34.75 Cr
Interest Expense 7.00 Cr6.00 Cr4.00 Cr4.00 Cr3.00 Cr4.00 Cr-4.00 Cr3.92 Cr3.26 Cr3.73 Cr3.18 Cr3.09 Cr
Pretax Income 59.00 Cr11.00 Cr20.00 Cr30.00 Cr30.00 Cr28.00 Cr-22.00 Cr19.09 Cr13.71 Cr-3.33 Cr-12.15 Cr22.79 Cr
Tax Provision 0000-3.00 Cr-28.00 L-0-3.94 L00017,000
Net Income 59.00 Cr9.00 Cr20.00 Cr29.00 Cr33.00 Cr29.00 Cr-21.00 Cr22.29 Cr14.91 Cr-5.72 Cr-12.61 Cr23.78 Cr
Diluted EPS 14.491.853.905.806.505.79-4.104.402.94-1.13-2.494.69

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 1,747.00 Cr873.00 Cr797.00 Cr683.00 Cr600.00 Cr484.00 Cr450.00 Cr-665.90 Cr819.07 Cr921.93 Cr811.33 Cr
Cost of Revenue --------397.18 Cr498.39 Cr544.22 Cr525.88 Cr
Gross Profit --------268.72 Cr320.68 Cr377.70 Cr285.45 Cr
Operating Expenses 1,429.00 Cr703.00 Cr794.00 Cr659.00 Cr612.00 Cr515.00 Cr421.00 Cr-239.05 Cr242.21 Cr120.91 Cr126.92 Cr
Operating Income -8.00 Cr26.00 Cr-138.00 Cr-109.00 Cr-142.00 Cr-149.00 Cr-80.00 Cr-29.67 Cr78.47 Cr256.80 Cr158.53 Cr
EBITDA 317.00 Cr171.00 Cr3.00 Cr24.00 Cr-12.00 Cr-31.00 Cr29.00 Cr-142.26 Cr141.54 Cr144.65 Cr69.73 Cr
Interest Expense 537.00 Cr294.00 Cr347.00 Cr310.00 Cr7.00 Cr6.00 Cr52.00 Cr-32.23 Cr16.35 Cr14.54 Cr13.26 Cr
Pretax Income -389.00 Cr-296.00 Cr-544.00 Cr-399.00 Cr69.00 Cr-131.00 Cr-117.00 Cr-55.25 Cr91.95 Cr95.56 Cr21.02 Cr
Tax Provision 190.61 Cr17.76 Cr48.96 Cr47.88 Cr0-0-0-0-3.12 Cr-19.35 L-19.16 L
Net Income -197.00 Cr-279.00 Cr-495.00 Cr-353.00 Cr69.00 Cr-131.00 Cr-117.00 Cr-46.32 Cr92.17 Cr99.66 Cr20.55 Cr
Diluted EPS -23.06-31.37-55.69-39.657.80-32.11-28.55-0.4811.3519.0619.65-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 4,061.00 Cr3,862.00 Cr3,256.00 Cr3,125.00 Cr3,077.00 Cr1,460.00 Cr1,237.00 Cr-1,225.21 Cr1,553.87 Cr1,687.91 Cr1,910.91 Cr
Current Assets --------501.01 Cr790.75 Cr807.42 Cr683.90 Cr
Cash & Equivalents --------22.60 Cr3.60 Cr21.11 Cr7.01 Cr
Inventory --------228.74 Cr149.36 Cr198.18 Cr256.41 Cr
Receivables --------215.19 Cr195.55 Cr241.83 Cr263.87 Cr
Total Liabilities --------536.56 Cr384.41 Cr420.63 Cr623.13 Cr
Current Liabilities --------371.89 Cr259.97 Cr285.57 Cr278.97 Cr
Long Term Debt --------148.84 Cr120.43 Cr131.64 Cr327.73 Cr
Total Debt 3,211.00 Cr3,215.00 Cr3,106.00 Cr3,202.00 Cr3,230.00 Cr566.00 Cr453.00 Cr-331.35 Cr135.18 Cr174.61 Cr362.59 Cr
Total Equity 329.00 Cr49.00 Cr-467.00 Cr-792.00 Cr-704.00 Cr766.00 Cr653.00 Cr-688.65 Cr1,169.47 Cr1,267.29 Cr1,287.79 Cr
Shares Outstanding --------4.08 Cr5.07 Cr5.07 Cr5.07 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -369.00 Cr212.00 Cr401.00 Cr9.00 Cr12.00 Cr81.00 Cr24.00 Cr-18.34 Cr125.99 Cr19.22 Cr101.20 Cr
Investing Cash Flow 1,334.00 Cr-1.00 Cr-176.00 Cr-28.00 Cr45.00 Cr167.00 Cr67.00 Cr--31.21 Cr-312.03 Cr-26.93 Cr-285.27 Cr
Financing Cash Flow -597.00 Cr-286.00 Cr-465.00 Cr33.00 Cr-0-250.00 Cr-165.00 Cr-31.17 Cr167.04 Cr25.22 Cr169.98 Cr
Capital Expenditure 1,334.00 Cr-1.00 Cr-9.00 Cr-6.00 Cr-7.00 Cr-4.00 Cr-1.00 Cr--84.91 Cr-64.81 Cr-150.11 Cr-383.58 Cr
Free Cash Flow 965.00 Cr211.00 Cr392.00 Cr3.00 Cr5.00 Cr77.00 Cr23.00 Cr--66.58 Cr61.18 Cr-130.89 Cr-282.39 Cr
Net Change in Cash 367.00 Cr-76.00 Cr-240.00 Cr15.00 Cr57.00 Cr-2.00 Cr-74.00 Cr-18.29 Cr-19.00 Cr17.51 Cr-14.10 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------40.4%39.2%41.0%35.2%
Operating Margin % -0.5%3.0%-17.3%-16.0%-23.7%-30.8%-17.8%-4.5%9.6%27.9%19.5%
Net Margin % -11.3%-32.0%-62.1%-51.7%11.5%-27.1%-26.0%-7.0%11.3%10.8%2.5%
ROE % -59.9%-569.4%106.0%44.6%-9.8%-17.1%-17.9%-6.7%7.9%7.9%1.6%
ROCE % --------3.5%6.1%18.3%9.7%

Shareholding Pattern

Insiders
69.84%
Institutions
18.05%
Public Float
59.85%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ORCHPHARMA

Google News Fri, 26 Jun 2026

ORCHPHARMA Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE5fSXY5Tk1yMG1Qb3plMW1xdmpzVnVTQkJ2V1ZTX1BMbTJxZU5NX1QyMVI4dEEyT2dYMkdzbi1UbUpzME5pNTZtaG9LSFkwdVhaN3BPcW5GcDdLWklSaThyOXVWYXFKazVYb0w5N0hIeEE3SnJhcDNBc2FpbzBvUQ?oc=5" target="_blan…

Google News Wed, 08 Jul 2026

INDIA STOCKS-Indian shares set to open lower as US-Iran tensions lift oil prices - marketscreener.com

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOS3FTUTJ0Mll5WmRfWEVQa2poeVE0Ump6WDVyS2ttS1lFdXV1ZG9CVVpsVnZYSHRRZjBabC1uR2FKVk5oTjJRa3FzMThvRktSRFU4SFdPeVFnMTNvdVczMU9WNEx0SWxBdVNyTzdYdnZXbUE5LWgxRmNGU21UMUstX0xqc0k4bDJuRDRpWn…

Google News Mon, 01 Jun 2026

Some May Be Optimistic About Orchid Pharma's (NSE:ORCHPHARMA) Earnings - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxPRVItT1o0WmNUZDNOWmR3bU5MMGlNM3V6WUt5WHVxQ05oX2ZkLWNJX0VWaG12UlZ2cHZYb2UyNUR3NFo0Wk4yWmNkRkNfRUJKc3d5ekwwa0JJc0syN1MxaWk4V3lHY0lfcnZnZVREVFhnRjczYUI5d1dmdmRta3pQeVRhTWd6UFgycEp6dG…

Google News Mon, 18 Aug 2025

Some Orchid Pharma Limited (NSE:ORCHPHARMA) Analysts Just Made A Major Cut To Next Year's Estimates - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPSWp5OVlpd2RJbW5DQzhfWmVNMnhZMXp5Q09vd3BmbVQ3NWExLVhEYjNsdURyY2Y0SGxOVHFGeWxndFZCV0J0MmhibnBsVU5jY3F4cnFnNlhGVUFxNG5aN2U5dlNHaUFPV3h1anY2MU5fc3lxOG9LdVZ5S3NpRkpxS0Z6N1dvbkVFUW8xNH…

Google News Wed, 12 Nov 2025

Orchid Pharma Shares Price Drop 4% on 92% YoY Q2 Profit Decline - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQYjEyOGdDWi1UQ05qdGlfbmhfSk92WXlHOFhhQnlwMWxsOHdUQVRESDJTci1xVHNBLVhBaUdJckh5cGI1NVpzY1RUc2paOXBWUFJFcm5MUGtybVNyd2JHU2owaHY3Vk5kZnAxUWNDNEZORW1YdXVXYXpacFZCbkpHdmswNk1BZ2NSOTdZTz…

Google News ue, 05 Aug 2025

There's Reason For Concern Over Orchid Pharma Limited's (NSE:ORCHPHARMA) Price - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxNM1FkeEF1bEpJMFNqQmxjU3BiVVdLTmxydF9XbE5GeU1oOG41Y0MySnJZV3Y4Q1ZUNFRBYkYxU1dreHROejZKVEdFRzkydmFMSzY4RDBoX2dUZFkwdEgwaXNKREhaM1pEQ2MyUl9GbFFRNzd4YXNGRlhxS0NNS0NkaU1tZVFpd1llREQ4a0…

ORCHPHARMA — Frequently Asked Questions

What is the current share price of Orchid Pharma Limited (ORCHPHARMA)?

As of 2026-07-15 09:52 IST, Orchid Pharma Limited (ORCHPHARMA) trades at ₹1,073.70 on NSE. Its 52-week range is ₹482.45 to ₹1,073.70.

What is the market capitalisation of ORCHPHARMA?

Orchid Pharma Limited (ORCHPHARMA) has a market capitalisation of ₹5,445.71 Cr on NSE.

What is the P/E ratio of ORCHPHARMA?

ORCHPHARMA trades at a trailing price-to-earnings (P/E) ratio of 54.64. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 3.97.

What is the return on equity (ROE) of ORCHPHARMA?

ORCHPHARMA has a return on equity (ROE) of 1.60%. Its return on capital employed (ROCE) is 2.10%.

Is ORCHPHARMA a good stock to buy?

This page provides a data-driven analysis of Orchid Pharma Limited (ORCHPHARMA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space